Abstract: Novel antifungal antibiotics Cepacidine A (A.sub.1 and A.sub.2 ),a novel microorganism Pseudomonas cepacia AF 2001 producing the same, and a process for producing the said antibiotics are disclosed.

Abstract: A process for producing a beverage composition containing pine sprout extract.

Abstract: Pyridone carboxylic acid compounds and pharmaceutically acceptable salts and physiologically hydrolyzable esters thereof are provided which are represented by the formula: ##STR1## wherein R.sub.1 is a lower alkyl, a halogen-substituted lower alkyl, a lower alkenyl, a cycloalkyl, or a substituted- or unsubstituted-phenyl group; R.sub.2 is a hydrogen atom, or a lower alkyl or an amino group; A is a nitrogen atom or the group C--X wherein X is a hydrogen or a halogen atom, or an alkoxy group; and Z is a group having the formula: ##STR2## wherein n is 1 or 2; R.sub.3 and R.sub.4 each represent a hydrogen atom or a lower alkyl group, with proviso that, if n is 2, one of R.sub.3 and R.sub.4 is a hydrogen atom; R.sub.5 and R.sub.6 each represent a hydrogen atom, or a hydroxy, a lower alkoxy or an amino group which is unsubstituted or substituted by a lower alkyl group, with proviso that one of R.sub.5 and R.sub.6 is a hydrogen atom; and R.sub.7 is a hydrogen atom or a lower alkyl group.

Abstract: A solid oral pharmaceutical formulations of novel pyridone carboxylic acid compounds and esters or salts thereof having powerful antibacterial activities is disclosed.

Abstract: Aqueous solutions of novel pyridone carboxylic acid compounds and esters or salts thereof having powerful antibacterial activities against both gram-negative and gram-positive bacteria, and in particular both ready-to-use injection and/or infusion solutions and dosage forms which can be converted into such injection and/or infusion solutions before use are disclosed.

Abstract: A Legionella specific antibiotic AL072 is disclosed. In addition the antibiotic is produced by the microorganism Streptomyces sp. AL91 KCCM 10055.Further, the antibiotic compound has a specified formula.

Abstract: Pyridone carboxylic acid compounds or physiologically hydrolyzable esters thereof are provided which are represented by the formula: ##STR1## wherein R.sub.1 is a lower alkyl, a halogen-substituted lower alkyl, a lower alkenyl, a cycloalkyl, or a substituted- or unsubstituted-phenyl group; R.sub.2 is a hydrogen atom, or a lower alkyl or an amino group; A is a nitrogen atom or the group C-X wherein X is a hydrogen or a halogen atom, or an alkoxy group; and Z is a group having the formula: ##STR2## wherein n is 1 or 2; R.sub.3 and R.sub.4 each represent a hydrogen atom or a lower alkyl group, with proviso that, if n is 2, one of R.sub.3 and R.sub.4 is a hydrogen atom; R.sub.5 and R.sub.6 each represent a hydrogen atom, or a hydroxy, a lower alkoxy or an amino group which is unsubstituted or substituted by a lower alkyl group, with proviso that one of R.sub.5 and R.sub.6 is a hydrogen atom; and R.sub.7 is a hydrogen atom or a lower alkyl group.

Abstract: A Legionella specific antibiotic AL072, a Streptomyces sp. AL91 producing the antibiotic, and a process for producing the antibiotic are disclosed. Further, the antibiotic compound has a specified formula. The formula is ##STR1## In addition the process also includes extraction of a culture broth provided by cultivating the microorganism Streptomyces sp. AL91, accession number KCCM 10055, with isopropyl alcohol and ethyl acetate to obtain an extract containing the antibiotic compound. The compound is then isolated from the extract by chromatography on a column filled with octadecyl silica gel and also by high pressure liquid chromatography.

Abstract: A Legionella specific antibiotic AL072 is disclosed. In addition the antibiotic is produced by the microorganism Streptomyces sp. AL91KCCM 10055. Further, the antibiotic compound has a specified formula.

Abstract: The present invention provides novel organic acid addition salts of a quinolone-carboxylic acid of formula (I) ##STR1## wherein Z is 5-oxotetrahydrofuran-2-carboxylic acid or 2-hydroxyglutaric acid. The salts are highly soluble in water and are thus suitable to prepare a stable injection in storage for a long period of time.

Abstract: The specification describes a process for producing human proinsulin in Escherichia coli (E. coli) using gene manipulation technology. The process can provide for human proinsulin in high yields by a novel expression vector having strong regulatory elements of an insulin gene and a stable recombinant gene product. The expression vector of the present invention is characterized in that: 1) it has an 11 amino acid leader peptide containing six threonines in order to ensure an intracellular stability of proinsulin fusion protein, 2) it contains two copies of a DNA expression cassette each comprising a strong lambda P.sub.R promoter, a lac ribosome binding site, a proinsulin gene with a 17 amino acid leader peptide sequence containing a DNA sequence encoding (Thr).sub.6, and a strong fd phage transcription terminator (combination of phage fd terminator and translation stop codon), etc.

Abstract: A process for preparing B-lactam derivatives of the formula (I): ##STR1## wherein R.sup.1 represents hydrogen or a metal salt; and R.sup.2 represents hydrogen, acetoxy methyl, (2,5-dihydro-2-methyl-6-hydroxy-5-oxo-as-triazin-3-yl)thiomethyl or (1-methyl-1-H-tetrazol-5-yl)thiomethyl is disclosed. This process comprises the steps of (a) reacting triphenylphosphine and hexachloroethane or carbon tetrachloride with 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid in an organic solvent to give the corresponding acyloxyphosphonium chloride derivative of the formula: ##STR2## (b) acylating a previously silylated derivative of 7-ACA with this acyloxyphosphonium chloride derivative without its isolation.

Abstract: Novel semi-synthetic cephalosporin derivatives having a fused pyridiniummethyl at 3-position of the cephem nucleus, pharmaceutically acceptable salts, physiologically hydrolizable esters or solvates thereof are disclosed. Also disclosed is a process for preparing the cephalosporin derivatives which comprises introducing a fused pyridiniummethyl substituent at 3-position of 7-.beta.-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-ca rboxylic acid derivatives. The compounds of the present invention show potent antibacterial activities and a broad spectrum against both gram-positive and gram-negative bacteria.